ClinicalTrials.gg
CompletedNCT02451007Updated Nov 19, 2019Results posted

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

A Phase 2 interventional study of lurbinectedin (PM01183) in Solid Tumors, sponsored by PharmaMar. Completed at 16 sites in 2 countries. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by PharmaMar · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
Up to 65 Years
Sex
All
01

Study summary

Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed and dated
  • Normal cardiac conduction and function (centrally read)
  • Blood pressure between 90 and 150 mmHg systolic, inclusive, and not higher than 90 mmHg diastolic.
  • Specific serum electrolyte levels

Exclusion criteria

Exclusion Criteria:

  • Age > 65 years
  • Performance status = 2 [ (ECOG)]
  • Heart rhythm disturbances
  • Significant ischemic coronary disease, heart failure, myocardial infarction, or unstable angina within the last six months.
  • Prior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) > 450 mg/m²
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    A (lurbinectedin)

    lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion

    Drug: lurbinectedin (PM01183)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in QTcF (QT Corrected According to Fridericia's Formula)

    ΔQTCF (Change in QTcF); EOI (end of infusion); LSM (Least Square Means); PK (Pharmacokinetic(s)). On Day 1 (D1) of Cycle 1 (C1), LSM ΔQTcF should have low difference values, without any clear trend to change with time. Therefore, the upper bound (UB) of the (two-sided) 90%Confidence Interval (CI) at all time points had to be less than the protocol-specified cut-off of 20 ms at each time point. If so, non-inferiority of any ECG time point to baseline with respect of QTc prolongation could be concluded

    Time frame: Scheduled post-baseline ECG time points were taken 5-10 min before their time-matched PK samples: i.e., 5 min before EOI, 30 min, 1, 3, 24, 72 and 168 hours after EOI of Cycle 1, and 5 min before EOI, 30 min, 1, 3 and 168 hours after EOI of Cycle 2.

Secondary outcomes

  1. Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)

    ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

    Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)

  2. Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)

    ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

    Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)

  3. Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)

    ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

    Time frame: Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)

07

Results

Posted Feb 18, 2019

Participant flow

This study was nested into a multicenter clinical trial with a competitive recruitment. From August 2015 to June 2016, a total of 39 evaluable patients at 12 sites in USA and Spain were included in this QT evaluation study with baseline and one or more postbaseline Electrocardiogram (ECG) assessments available.

Participant flow — Overall Study
MilestoneGroup A - Lurbinectedin (PM01183)
Started39
Completed32
Not completed7
Withdrew: Withdrawal by subject4
Withdrew: Adverse event1
Withdrew: Disease progression2

Outcome measures

PrimaryChange in QTcF (QT Corrected According to Fridericia's Formula)

ΔQTCF (Change in QTcF); EOI (end of infusion); LSM (Least Square Means); PK (Pharmacokinetic(s)). On Day 1 (D1) of Cycle 1 (C1), LSM ΔQTcF should have low difference values, without any clear trend to change with time. Therefore, the upper bound (UB) of the (two-sided) 90%Confidence Interval (CI) at all time points had to be less than the protocol-specified cut-off of 20 ms at each time point. If so, non-inferiority of any ECG time point to baseline with respect of QTc prolongation could be concluded

Time frame:
Scheduled post-baseline ECG time points were taken 5-10 min before their time-matched PK samples: i.e., 5 min before EOI, 30 min, 1, 3, 24, 72 and 168 hours after EOI of Cycle 1, and 5 min before EOI, 30 min, 1, 3 and 168 hours after EOI of Cycle 2.
Reported as:
Least squares mean · ms (Milliseconds)
Change in QTcF (QT Corrected According to Fridericia's Formula)
ms (Milliseconds)Group A - Lurbinectedin (PM01183)
Cycle 1 - 5 min before EOI3.32 (1.12 to 5.51)
Cycle 1 - 30 min after EOI1.76 (-0.41 to 3.93)
Cycle 1 - 1 hour after EOI1.84 (-1.02 to 4.69)
Cycle 1 - 3 hour after EOI1.32 (-1.40 to 4.05)
Cycle 1 - 24 hour after EOI-8.24 (-11.2 to -5.26)
Cycle 1 - 72 hour after EOI-12.4 (-15.4 to -9.39)
Cycle 1 - 168 hour after EOI-5.20 (-7.98 to -2.41)
Cycle 2 - Before start of infusion-0.46 (-3.27 to 2.35)
Cycle 2 - 5 min before EOI2.25 (-1.18 to 5.68)
Cycle 2 - 30 min after EOI2.32 (-1.02 to 5.66)
Cycle 2 - 1 hour after EOI2.73 (-1.08 to 6.54)
Cycle 2 - 3 hour after EOI5.39 (1.17 to 9.60)
Cycle 2 - 168 hour after EOI-4.22 (-7.36 to -1.08)
SecondaryRelationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)

ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

Time frame:
Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
Reported as:
Mean · Microgram/milliliter (μg/mL)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)
Microgram/milliliter (μg/mL)Group A - Lurbinectedin (PM01183)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)2.06 (1.42 to 2.71)
SecondaryRelationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)

ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

Time frame:
Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
Reported as:
Mean · Milliseconds (ms)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)
Milliseconds (ms)Group A - Lurbinectedin (PM01183)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)2.94 (0.79 to 5.10)
SecondaryRelationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)

ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cmax (Maximum Plasma Concentration). Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax.

Time frame:
Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks)
Reported as:
Number · Unitless
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)
UnitlessGroup A - Lurbinectedin (PM01183)
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)-6.40 (-8.44 to -4.35)

Adverse events

Collected over Through study completion, each patient had to be followed for 2 cycles (1 cycle =3 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A - Lurbinectedin (PM01183)13/39 (33.3%)9/39 (23.1%)35/39 (89.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventGroup A - Lurbinectedin (PM01183)
Abdominal painGastrointestinal disorders3/39
Blood calcium decreasedInvestigations1/39
Blood phosphorus decreasedInvestigations1/39
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/39
AspirationRespiratory, thoracic and mediastinal disorders1/39
Febrile neutropeniaBlood and lymphatic system disorders1/39
Facial paralysisNervous system disorders1/39
General physical health deteriorationGeneral disorders1/39
Small intestinal obstructionGastrointestinal disorders1/39
CholangitisHepatobiliary disorders1/39
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGroup A - Lurbinectedin (PM01183)
NauseaGastrointestinal disorders19/39
FatigueGeneral disorders15/39
ConstipationGastrointestinal disorders8/39
VomitingGastrointestinal disorders7/39
NeutropeniaBlood and lymphatic system disorders6/39
Abdominal painGastrointestinal disorders6/39
HeadacheNervous system disorders4/39
PyrexiaGeneral disorders4/39
Decreased appetiteMetabolism and nutrition disorders4/39
AnaemiaBlood and lymphatic system disorders3/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group A - Lurbinectedin (PM01183)
<=18 years0
Between 18 and 65 years37
>=65 years2
Age, Continuous
Age, Continuous(years)Group A - Lurbinectedin (PM01183)
Median56 (28 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Group A - Lurbinectedin (PM01183)
Female22
Male17
Region of Enrollment
Region of Enrollment(Participants)Group A - Lurbinectedin (PM01183)
United States14
Spain25
08

Study locations

16 sites
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Dana Farber Cancer lnstitute
    Boston, Massachusetts 02215, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Hospital Universitari Vall D'Hebron
    Barcelona, 08035, Spain
  • Complejo Hospitalario Regional Reina Sofía
    Córdoba, 14004, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 280035, Spain
  • Hospital Ramón Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Complejo Hospitalario de Especialidades Virgen de La Victoria
    Málaga, 29010, Spain
  • Complexo Hospitalario Universitario de Santiago
    Santiago De Compostela, 15706, Spain
  • Hospital Universitari I Politècnic La Fe
    Valencia, 46026, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Aug 2016, 12 months.

Results were first posted in Feb 2019, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2015
First posted
May 21, 2015
StartActual
Aug 12, 2015
Primary completionActual
Aug 19, 2016
CompletionActual
Aug 19, 2016
Results first posted
Feb 18, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02451007
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
May 21, 2015
Start date
Aug 12, 2015
Primary completion
Aug 19, 2016
Completion
Aug 19, 2016
Results posted
Feb 18, 2019
Last update
Nov 19, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion